化学
组蛋白脱乙酰基酶
HDAC6型
雌激素受体
药理学
富维斯特朗
四氢异喹啉
乙酰化
癌症研究
生物化学
乳腺癌
组蛋白
癌症
立体化学
生物
基因
遗传学
作者
Guoshun Luo,Xin Lin,Shengnan Ren,Shuangjie Wu,Xin Wang,Luyu Ma,Hua Xiang
标识
DOI:10.1016/j.ejmech.2021.113870
摘要
Concomitant inhibition of estrogen receptor alpha (ERα) and histone deacetylase (HDAC) signaling has been proven effective in endocrine-resistant ER+ breast cancers. Herein, a series of tetrahydroisoquinoline (THIQ)-hydroxamate conjugates were rationally designed and synthesized as dual SERDs/HDAC inhibitors by incorporating the hydroxamate, a known HDAC pharmacophore, into a privileged THIQ scaffold of selective ERα degraders (SERDs). Some of these THIQ-hydroxamate conjugates displayed remarkable HDAC6 inhibition and improved antiproliferative activity against MCF-7 cells. Particularly, the most potent HDAC inhibitor 19k also exhibits potent ERα binding affinity, good ERα degradation efficacy and the best antiproliferative activity. Besides, 19k displayed superior antitumor efficacy than the drug combination (Fulvestrant + SAHA) through promoting ERα degradation and histone acetylation in an MCF-7 xenograft model, without causing observable toxicity. Collectively, this study validates the therapeutic potential of a dual-acting compound with potent ERα degradation efficacy and HDAC6 inhibition in breast cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI